Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

The drug provides both bronchodilation and anti-inflammatory properties in a single molecule and is administered ... IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the lung ...

According to the report, fitusiran could become the first antithrombin-lowering therapy based on a double-stranded RNA molecule, pending approval, and has a sales prediction of $1 billion.

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

Single-molecule biophysics is the study of the dynamics and interactions of individual biomolecules to understand how they carry out their functions in living cells. For example, monitoring the ...

Jan. 13, 2025 — Scientists have found that a test to detect circulating tumor DNA can predict lung cancer ... Lung Cancer Test Predicts Survival in Early Stages Better Than Current Methods Jan ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

For example, a growing number of allergic patients (e.g., asthma, atopic dermatitis) are being treated with biologics that block the IL-4/IL-13 axis (e.g., dupilumab, an anti-IL-4Rα mAb) (82, 120).

Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing course, with a potentially ...